The Pharmacy Times® Pharmacy Hospital Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to hospital and health-system pharmacists.
April 27th 2025
Zoldonrasib, a novel oral KRAS G12D-selective inhibitor, demonstrated promising safety and early antitumor activity in patients with previously treated non–small cell lung cancer (NSCLC), offering a potential new targeted therapy for this underserved population.
FDA Expands Indication of Lorlatinib for ALK-Positive Non–Small Cell Lung Cancer
March 4th 2021The FDA has approved a supplemental new drug application for lorlatinib (Lorbrena) to expand the indication to include the frontline treatment of patients with ALK-positive non–small cell lung cancer.
Read More
Study: Structured Exercise Program Benefited Men’s Artery Health, Not Testosterone Therapy
February 26th 2021The investigators said testosterone therapy may have some benefits for older men, but they did not find any benefits in artery function, which is a determinant of future cardiovascular risk.
Read More
Tip of the Week: Strategic Planning for Pharmacy Emergency Preparedness and Response Activities
February 26th 2021Pharmacy organizations have produced advisories to guide workflow and optimize services, yet there still exists a gap in further integration of pharmacists into public health and safety initiatives.
Read More
FDA Approves Libtayo as Monotherapy for Advanced Non-Small Cell Lung Cancer
February 23rd 2021This is the third approval for Libtayo, following approvals as the first immunotherapy for patients with advanced basal cell carcinoma and as the first systemic treatment for advanced cutaneous squamous cell carcinoma.
Read More